Live
- Google Cloud unveils new initiatives to empower AI startups in India
- Collector Warns of Strict Action if Irregularities Occur in Weighing Process
- WPL 2025: Mumbai Indians release Issy Wong, Humairaa Kaazi, Fatima Jaffer and Priyanka Bala
- People will not forgive Congress for repeatedly insulting Constitution: Kiren Rijiju
- Aid group resumes activities at famine-hit camp in Sudan
- Kishan Reddy Vows to End BRS and Congress Influence in Telangana, Criticizes CM's Governance
- Punjab bypolls: Bittu twisting words for political gains, says Congress nominee
- Punjab CM to administer oath to over 10,000 sarpanches on Friday
- BJP Core Committee Plans Protests Against State Government’s Failures
- Mulugu Collector Divakar's Facebook Hacked Again, Cyber Criminals Send Fraudulent Messages Asking for Money
Dr Reddy's launches Treprostinil injection in US
Representational image
Highlights
City-based pharmaceutical company Dr Reddy’s Laboratories Limited on Friday announced the launch of Treprostinil Injection in the U S market.
Hyderabad: City-based pharmaceutical company Dr Reddy's Laboratories Limited on Friday announced the launch of Treprostinil Injection in the U S market.
A therapeutic equivalent generic version of Remodulin, Treprostinil injection is approved by the U S Food and Drug Administration (USFDA).
Dr Reddy's new launch is supplied in 20 mg/20 ml, 50 mg/20 ml, 100 mg/20 ml or 200mg/20 ml vials. Treprostinil injection is a prostacyclin mimetic indicated for patients who require transition from epoprostenol, to reduce the rate of clinical deterioration, the drug maker said.
Next Story
ADVERTISEMENT
